News
ZLAB
19.15
+0.79%
0.15
Weekly Report: what happened at ZLAB last week (0622-0626)?
Weekly Report · 2d ago
Zai Lab Director William Lis disposes of 7,040 shares for $127,353.6
PUBT · 06/24 20:06
Zai Lab files HKEX next-day disclosure return reporting 3.7 million new shares issued under equity incentive plans
PUBT · 06/22 12:42
Zai Lab grants directors 178,968 restricted shares under 2024 equity incentive plan
PUBT · 06/22 11:58
Weekly Report: what happened at ZLAB last week (0615-0619)?
Weekly Report · 06/22 09:47
Novocure falls after late-stage trial setback for cancer treatment device
Seeking Alpha · 06/18 11:51
Zai Lab shareholders approved 10% share issuance mandate at annual meeting
PUBT · 06/18 00:28
Zai Lab Shareholders Approve Directors, Auditors and Mandates
TipRanks · 06/17 21:22
Zai Lab shareholders approve 10% share repurchase mandate at annual meeting
PUBT · 06/17 20:06
Zai Lab Announces EMA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3-Targeting Antibody-Drug Conjugate, For Treatment Of Pulmonary Neuroendocrine Carcinomas
Benzinga · 06/16 11:14
Zai Lab announces EMA granted ODD to zocilurtatug pelitecan
TipRanks · 06/16 11:06
Zai Lab says EMA grants orphan drug status to Zocilurtatug Pelitecan for pulmonary neuroendocrine carcinomas
PUBT · 06/16 11:01
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Barchart · 06/16 06:00
Weekly Report: what happened at ZLAB last week (0608-0612)?
Weekly Report · 06/15 09:48
Pfizer, Zai Lab win China nod for cervical cancer therapy Tivdak
Seeking Alpha · 06/09 11:30
Zai Lab says China NMPA approves TIVDAK for recurrent or metastatic cervical cancer
PUBT · 06/09 00:34
ZAI LAB RECEIVES CHINA NMPA APPROVAL OF TIVDAK® (TISOTUMAB VEDOTIN FOR INJECTION) FOR THE TREATMENT OF ADULT PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER
Reuters · 06/09 00:34
Zai Lab files initial beneficial ownership statement for Operating Partner Wang Yizhe
PUBT · 06/08 20:28
Weekly Report: what happened at ZLAB last week (0601-0605)?
Weekly Report · 06/08 09:46
Zai Lab grants 500 restricted share units under 2024 equity incentive plan
PUBT · 06/03 13:19
More
Webull provides a variety of real-time ZLAB stock news. You can receive the latest news about Zai Lab Limited through multiple platforms. This information may help you make smarter investment decisions.
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.